KR101148098B1 - Composition comprising 1-[4-4-nitro-penoxy-phenyl]-propane-1-one for preventing and treating the disease caused by Toxoplasmosis and Coccidium - Google Patents

Abstract

The present invention relates to a composition containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one (1434NJ0221) having coccidium inhibitory activity, in detail. Of 1- [4- (4-nitro-phenoxy) -phenyl] -propane-1-one (1434NJ0221) exhibits an excellent inhibitory effect on the growth of coccidium, that is, toxoplasma spp. It can be usefully used for the prevention and treatment of diseases.

Description

Composition for the prevention and treatment of diseases caused by toxoplasma worm and coccidium containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one as an active ingredient {Composition comprising 1- [4 -(4-nitro-penoxy) -phenyl] -propane-1-one for preventing and treating the disease caused by Toxoplasmosis and Coccidium}

The present invention relates to a composition for the prevention and treatment of diseases caused by toxoplasma worms and coccidial containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one as an active ingredient.

Document 1 C.M. Jin et al., Experimental Parasitology, 121 (2), pp132-136, 2009

[Reference 2] Jiang JH, Jin CM, Kim YC, Kim HS, Park WC, Park H., Biol Pharm Bull. 31 (12): 2273-6, 2008

[Document 3] McFadden DC, Seeber F., Boothroyd JC, Antimicrob. Agents Chemother., 41, 1849-1853, 1997

[Document 4] Georgiev VS, Drugs, 48 , 179-188,1994

[Reference 5] Jang, S. I., Jun, M. H., Lillehoj, H. S., Dalloul, R. A., Kong, I. K., Kim, S. and Min, W. G. Anticoccidial effect of green tea-based diets against Eimeria maxima. Vet. Parasitol. 144: 172-175, 2007

[6] Daugschies et al. Veterinary Parasitology 103, pp. 299-308, 2002

Coccidium, including the toxoplasma spp. And Eimeria tenella , causes major diseases and causes great damage to livestock and humans. Antibiotics have been mainly used as a treatment and prevention agent for coccidium, but the treatment efficiency is relatively low, antibiotic resistance protozoa emerges, and residual toxicity problem arises (Daugschies et al. Veterinary Parasitology 103, pp. 299-308, 2002).

In industrial animals, coccidiosis causes significant economic losses, including livestock mortality, reduced feed efficiency, reduced weight gains, increased costs and increased labor costs. In particular, the poultry industry and the pig industry are the main breeders that suffer the most damage from coccidium infection. Coccidium infectious agents in the poultry industry are Eimeria, Leucocytozoon , Haemoproteus , Toxoplasma , Sarcocystis And Cryptosporidium have been reported, but among them, the damage caused by Eimeria is known to be the most serious. The main causes of coccidium infection in the swine industry are Eimeria , Isospora and Cryptosporidia And Toxoplasma . The clinical symptoms of these coccidial infections are mainly anorexia, diarrhea and weight loss, with low mortality. In the poultry industry, economic losses from coccidium have been reported to cause more than US $ 1.5 billion per year in damages in the US alone (Weber, 1997), with pigs losing 15% per capita in denmaarc (Bayer Health Care). ), The economic damage from this is expected to be enormous. Preventive measures for coccidial infections in industrial animals include farm house cleanliness and disinfection, preventive administration of anticoccidial agents, blocking of major media such as rodents and utensils, and radio wave breakage between farms. It is, but it is not yet commercialized. In addition, anticoccidial agents such as ionophores, sulphonamides, diclazuril, amprolium, and furozolidone are used for the treatment of the disease.However, anticoccidial abuse and the emergence of resistant insects require significant amounts and seals for treatment. The situation is urgently needed. In particular, most of the currently distributed feed contains anticoccidial for feed additives, and because of the nature of the protozoa that makes it easier to acquire resistance, the elimination of coccidial with anticoccidial agent is far-reaching (Daugschies et al. Veterinary Parasitology 103, pp. 299-308, 2002).

Therefore, the development of new drugs is urgent, but the cost of new drug development is enormous, the additional cost of efficacy test, and the difficulty of redeveloping another new drug when obtaining resistance are difficult to develop anticoccidial drug in leading pharmaceutical companies. Are going through. Due to the problems of anticoccidial drugs, many researchers have recently focused their research on developing drugs that can solve the problem of acquiring resistance, but there is no clear development result.

Recently, the research trend of medicines are getting serious side effects, toxicity and resistance, so the research on the development of medicines from natural products is actively being carried out worldwide. In order to be effectively used for the treatment of diseases, the therapeutic dose should not be toxic to the host and the insecticidal effect to the infectious agent should be very large. However, the new drug is less toxic and effective for resistant parasites. Research is needed to reduce the appearance and toxicity of resistant parasites.

Accordingly, the inventors of the present invention, while identifying the toxoplasma worms and substances having the inhibitory effect of coccidium, the 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one compound of the present invention is toxin scavenger and cocci The present invention was completed by confirming the excellent inhibitory effect on the medium.

 In order to achieve the above object, the present invention is a toxophosphate and cocci containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one represented by the following formula (A) as an active ingredient It provides a pharmaceutical composition for the prevention and treatment of diseases caused by the medium.

Toxosporicidal and coccidium inhibitory composition of the present invention comprises 0.1 to 50% by weight of the compound relative to the total weight of the composition.

In addition, the present invention is a disease caused by toxoplasma worms and coccidium containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one represented by the following general formula (A) as an active ingredient: It provides a veterinary composition for the prevention and treatment of.

In addition, the target animals of the toxoplasma worms and coccidium include mammals such as pigs, cows and goats; Fish such as carp and goldfish; And poultry such as pheasants, chickens, ducks, turkeys and the like.

Pharmaceutically acceptable salts of the compounds of this invention can be exemplified by acid addition salts formed with pharmaceutically acceptable free acids. Organic acids or inorganic acids may be used as the free acid, and citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, Galacturonic acid, embonic acid, glutamic acid, citric acid and aspartic acid may be used, and inorganic acids may be hydrochloric acid, bromic acid, sulfuric acid, sulfurous acid and phosphoric acid, preferably methanesulfonic acid and hydrochloric acid.

The acid addition salt used in the present invention is a conventional method, i.e., the compound of formula (A) is dissolved in a water miscible organic solvent such as acetone, methanol, ethanol and acetonitrile and an excess of an organic acid is added, or an acid aqueous solution of an inorganic acid. After addition of the precipitate or crystallization, the mixture may be prepared by evaporating the solvent or excess acid and then drying or suction filtering the precipitated salt.

Hereinafter, the present invention will be described in detail.

It provides a method for producing the compound of the present invention as follows.

(Scheme 1)

As shown in Scheme 1,

The compound of Chemical Formula 1 is 4-hydroxy propiophenone as a starting material using 4-bromo nitrobenzene in the amount of 1 to 2 equivalents, coupling reaction in the presence of 1 to 3 equivalents of base and 0.1 to 1 equivalents of copper catalyst To prepare.

In the reaction, the base may be K ₂ CO ₃ or Na ₂ CO ₃ and the like, and as a copper catalyst, copper (II) oxide (CuO), copper (I) oxide (Cu ₂ O), copper acetate (Cu (OAc ₂ ), Copper bromide dimethylsulfide complex (CuBr.Me ₂ S) or Cu powder, more preferably K ₂ CO ₃ to CuO. The reaction solvent is pyridine, acetonitrile and N, N-dimethylformamide, more preferably in a pyridine solvent. The reaction temperature is from room temperature to the boiling point of the solvent. At this time, the starting material may be commercially available.

The pharmaceutical composition comprising the compound of the present invention may further include appropriate carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

Veterinary dosage forms of the compounds of the present invention may also be used in the form of their veterinary acceptable salts, and include all solvates, hydrates and stereoisomers that may be prepared therefrom and may also be used alone or in other veterinary activities. It can be used in a suitable collection as well as in combination with a compound.

Veterinary compositions comprising a compound of the present invention may further comprise suitable excipients and diluents commonly used in the manufacture of veterinary compositions.

Excipients and diluents that may be included in the veterinary composition comprising the compound of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, Sorbitan monostearate, polysorbate 60, methylparaben, propylparaben and mineral oil.

The veterinary composition comprising the compound of the present invention may further include a filler, an anticoagulant, a lubricant, a humectant, a spice, an emulsifier, a preservative, and the like. Formulations may be formulated using methods well known in the art to provide rapid, sustained or delayed release, wherein the formulations are powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard Gelatin capsules, suppositories, sterile injectable solutions, sterile external preparations, and the like.

The veterinary composition according to the present invention may vary depending on the age, sex and weight of the animal, but may be administered once to several times in an amount of 0.1 to 100 mg / kg. In addition, the dosage of the compound may be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age and the like. Accordingly, the dosage is not limited in any way to the scope of the present invention. It may further comprise a suitable carrier, excipient and diluent commonly used.

Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Compositions comprising the compounds of the invention are each formulated in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, according to conventional methods Can be used.

Specifically, when formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants that are commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and the like may include at least one excipient in the compound, for example, starch, calcium carbonate, sucrose. ), Lactose, gelatin and the like can be mixed. In addition to the simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solvents, emulsions and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances and preservatives, in addition to the commonly used simple diluents, water and liquid paraffin. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. As the non-aqueous solvent and suspending agent, vegetable oils such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter and glycerogelatin can be used.

Preferred dosages of the compounds of the present invention depend on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, but may be appropriately selected by those skilled in the art. However, for the desired effect, the compound of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 10 mg / kg. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the pharmaceutical dosage forms of the compounds of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.

The pharmaceutical composition of the present invention can be administered to various mammals such as mice, mice, livestock, humans, and the like. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural and Intracerebroventricular injections.

In addition, the present invention provides an adjuvant for the prevention and treatment of diseases caused by toxoplasma spp. And coccidium containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one as an active ingredient. To provide.

As mentioned above, the 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one of the present invention exhibits an excellent inhibitory effect on the proliferation of toxoplasma worms, thereby preventing toxoplasma worms and coccidium. And therapeutic pharmaceutical compositions, veterinary compositions, and adjuvant supplements.

1 is a diagram showing the in vivo inhibitory effect of 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one on antitoxoplasmosis activity,
2 is a diagram showing the number of eggs in feces,
3 is a diagram showing the coccidium inhibitory effect of 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one after 6 days of coccidial infection,
4 is a diagram showing the inhibitory effect of coccidium of 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one 7 days after coccidium infection.
5 is a diagram showing the effect of inhibiting coccidium of 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one after 9 days of coccidium infection.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.

However, the following Examples and Experimental Examples are only illustrative of the present invention, the contents of the present invention is not limited by the following Examples, Reference Examples and Experimental Examples.

Example  1.1- [4- (4-nitro- Phenoxy ) - Phenyl Synthesis of] -propane-1-one Compound

In the present invention, the molecular structure was confirmed by comparing infrared spectroscopy, nuclear magnetic resonance spectra, mass spectroscopy, liquid chromatography, X-ray structure determination, photoluminescence measurement and elemental analysis calculations and actual measurements of representative compounds.

5 g (33.3 mmol) of 4-hydroxy propiophenone and 7.4 g (36.6 mmol) of 4-bromo nitrobenzene were dissolved in 50 ml of pyridine, 9.3 g (66.6 mmol) of K ₂ CO ₃ and 1.3 g (16.65 mmol) of CuO. After the addition was stirred for 72 hours at a temperature of 120 ^° C. The reaction solution was cooled to room temperature, filtered through celite, and concentrated under reduced pressure to remove the solvent. The remaining residue was purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1) and recrystallized from a mixed solvent of ethyl ether-hexane to yield 7.49 g (yield 83%) of the title compound as a pale yellow solid. Hereinafter referred to as "1434NJ0221").

¹ H NMR (300 MHz, CDCl 3): δ = 1.24 (t, 3H), 3.00 (q, 2H), 7.08-7.15 (m, 4H), 8.04 (d, 2H, J = 8.8 Hz), 8.25 (d , 2H, J = 8.8 Hz)

MS (m / e, M +): 271

(Scheme 1)

Reference Example  1. Preparation of Toxoplasma

The tachyzoite of RH strain of Toxoplasma gondii (ATCC, No. 50174) used in anti-toxoplasma worm experiment was obtained from ICR female mouse (KOATECH Co., Korea). A nutrient type of ¹ × 10 ⁵ toxoplasma worms was injected into the abdominal cavity of 6-week-old ICR mice, and four days later, the mice died of cervical distal bone. 5 ml of RPMI 1640 media (GIBCO, Lot No. 1346255) containing 2% FBS (GIBCO, Lot No. 1315128) was injected into the abdominal cavity twice, gently massaged for 1 minute and 30 seconds, and then extracted again. After centrifugation at 500 RPM for 5 minutes, the precipitate was discarded and the supernatant was transferred to a new 50 ml tube and centrifuged at 500 RPM for 5 minutes. The supernatant thus obtained was resuspended and immediately counted in a RPMI 1640 medium containing 10% FBS of the nutrient type of the relatively pure toxoplasma worm. Some of these were used for in vivo and in vitro experiments and some were again injected and maintained in new ICR mice (CM Jin et al., Experimental Parasitology, 121 (2), pp132-136). , 2009).

Reference Example  2. HeLa  Cell culture

Purchased from Korea Cell Line Bank HeLa cells were cultured in a 5% CO 2 incubator at 37 ° C. using RPMI 1640 medium containing 10% FBS.

Experimental Example  1.1- [4- (4-nitro- Phenoxy ) - Phenyl ] -Propane-1-one (1434) NJ0221 )of Antitoxin  Active test

In order to investigate the toxoplasmidosis inhibitory activity of 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one (1434NJ0221) in vitro, using the method described in the literature, Experiments such as (CM Jin et al., Experimental Parasitology, 121 (2), pp132-136, 2009).

HeLa cells purchased from Korea Cell Line Bank were inoculated in 96well at 2x10 ³ / well at 6 hours and replaced with RPMI 1640 medium containing 2% FBS, and after 18 hours, RPMI 1640 medium containing 2% FBS. Exchange and toxoplasmosis of the toxoplasma worms were treated 5 times the HeLa cell number. After 24 hours, compounds and control pyrimethamine were treated by concentration. After culturing for 24 hours, cell titer 96 Aqueous one solution cell proliferation assay (PROMEGAL, Lot No .: 22257902) was performed, and after 2 hours, absorbance was measured at 490 nm. Concentrations that inhibit the proliferation of Toxoplasma spp. (EC ₅₀ ; 50% cell proliferation inhibitory concentration) were calculated as shown in Equation 1 below to determine the drug efficacy coefficient selectivity.

After processing the compound, the cell proliferation assay examined the selectivity.

It showed higher selectivity than pyrimethamine, an antitoxoplasma drug currently in use in HeLa cells (see Table 1).

Experimental Example  2. Antitoxin  Active in vivo ( in vivo ) Experiment

In order to investigate the antitoxoplasmosis activity in vivo, the following experiments were carried out using the method described in the literature (JH Jiang et al., Biol. Pharm. Bull. 31: 2273-6, 2008) ).

^Five 1x10 trophic types of toxoplasma worms are injected into the abdominal cavity of 6-week-old ICR female mice. After 2 hours of infusion, the compound was orally administered for 4 consecutive days at 100 mg / kg / day, and the last day mice died of cervical distal bone. The trophic type of toxoplasma intraperitoneal was obtained and quantified.

As a result of the experiment, the 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one (1434NJ0221) compound of the present invention showed a 43% inhibitory effect in vivo (see FIG. 1).

Experimental Example  3. Cocodium Eimeriatenella, Eggs  Ready

Coccidium oocytes were stored in a potassium diclomate solution at a number of 8.5 × 10 ⁴ / ml, and the preservatives were toxic and thus washed. Discard the stock solution and put the sterile DW by the amount of the stock solution was centrifuged three times for 4,000 rpm, 25 minutes. Each time centrifugation, the supernatant was discarded and the same amount of DW was added. After washing, the egg was counted to determine the concentration. The dilution containing eggs was first diluted 20 times with DW, diluted 5 times with saturated sodium chloride (saturated NaCl) (typically 5-10 times), and counted using a chamber at x100 magnification. The final concentration of eggs is 4.3 × 10 ⁴ / ml.

Experimental Example  4. Hangcocksidium ( Anticoccidial In vivo (active) in vivo ) Experiment

In order to investigate the coccidium inhibitory activity in vivo, the following experiment was performed using the method described in the literature (Jang, SI, et al., Vet. Parasitol. 144: 172-175, 2007 ).

After adapting the feed for 3 days before infection to the meat, the oral infection was performed at a concentration of 10 ⁴ / ml per animal. The drug is administered orally for 4 days after infection. The drug was used as 1434NJ0221, and the experiment was divided into two control groups, an infected group and a non-infected group, which were administered only DMSO (10 numbers per group). Appropriate oral dose of the drug was administered 100mg / kg twice a day (morning and evening), and in the case of the control group, only DMSO was administered at the same concentration.

All feces in the chicken coop were removed the day after the end of the medication period and feces were collected daily for 5 days from the next day. The collected fecal samples were counted in the feces by dilution. That is, first, 1000-fold dilution with D.W. and then homogenized, the first dilution, the second dilution with saturated sodium chloride (saturated NaCl) was counted using a chamber (chamber) at × 100 magnification (see Fig. 2).

As a result of the experiment, 1434NJ0221 compound of the present invention showed an inhibitory effect of 83.7% in vivo at 6 days after infection, and 4434% of the 1434NJ0221 compound of the present invention at 7 days after infection, respectively. . In particular, at 9 days after infection, the 1434NJ0221 compound of the present invention showed a 93.3% inhibitory effect, and the 1434NJ0221 compound showed a sustained inhibitory effect for 4 days (FIG. 3; FIG. 4; FIG. 5).

Hereinafter, the preparation examples of the composition containing the compound of the present invention will be described, but the present invention is not intended to limit the present invention, but is only intended to be described in detail.

Formulation example  One. Powder  Produce

1434NJ0221 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

1434NJ0221 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

Formulation example  3. Preparation of capsules

1434NJ0221 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

1434NJ0221 10 mg

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

Na2HPO4,12H2O 26 mg

(2 ml) per 1 ampoule according to the usual injection preparation method.

Formulation example  5. Liquid  Produce

1434NJ0221 20 mg

10 g of isomerized sugar

5 g of mannitol

Purified water

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

Claims (5)

Prevention of toxoplasmosis due to toxoplasma and coccidium containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one represented by the following structural formula (A), and Therapeutic Pharmaceutical Compositions:

(A) The pharmaceutical composition of claim 1, wherein the compound comprises 0.1 to 50% by weight of the compound, based on the total weight of the composition. Toxoplasmosis and toxoplasmosis due to coccidial containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one represented by the structural formula (A) of claim 1 as an active ingredient Prophylactic and therapeutic veterinary compositions. The veterinary composition of claim 1, wherein the toxin scavenger and coccidial bacterial infection is a mammal, fish or poultry. Toxoplasmosis and toxoplasmosis due to coccidial containing 1- [4- (4-nitro-phenoxy) -phenyl] -propan-1-one represented by the structural formula (A) of claim 1 as an active ingredient Antigen supplements for prevention and treatment.

Images